Health Catalyst, Inc. (HCAT) — SEC Filings

Health Catalyst, Inc. (HCAT) — 34 SEC filings. Latest: 8-K (Apr 27, 2026). Includes 13 8-K, 7 SC 13G/A, 6 10-Q.

View Health Catalyst, Inc. on SEC EDGAR

Overview

Health Catalyst, Inc. (HCAT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 27, 2026: On April 24, 2026, Health Catalyst, Inc. filed an 8-K report detailing the departure of certain officers and the appointment of new ones. The filing also includes information on compensatory arrangements for these officers and other events. Specific details regarding the individuals involved and the

Sentiment Summary

Across 34 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral, 2 mixed. The dominant filing sentiment for Health Catalyst, Inc. is neutral.

Filing Type Overview

Health Catalyst, Inc. (HCAT) has filed 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K/A, 2 10-K, 2 SC 13G, 7 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent SEC Filings (34)

Health Catalyst, Inc. SEC Filing History
DateFormDescriptionRisk
Apr 27, 20268-KHealth Catalyst Announces Officer Changesmedium
Dec 2, 20258-KHealth Catalyst Announces Material Agreement, Officer Changesmedium
Nov 10, 202510-QHealth Catalyst's Net Loss Widens Amid Goodwill Impairment, Debt Repaymenthigh
Sep 10, 20258-KHealth Catalyst Announces Board and Executive Changesmedium
Aug 8, 202510-QHealth Catalyst's Revenue Climbs, But Net Loss Widens in Q2medium
Aug 7, 20258-KHealth Catalyst Announces Board and Executive Changesmedium
Jul 10, 20258-KHealth Catalyst Sets 2025 Annual Meeting Datelow
May 19, 2025DEF 14AHealth Catalyst DEF 14A: Executive Compensation Detailslow
May 9, 202510-QHealth Catalyst Q1 2025 Revenue Soarsmedium
May 7, 20258-KHealth Catalyst Files 8-K on Financialslow
Apr 30, 202510-K/AHealth Catalyst Files 2024 Annual Report Amendmentlow
Feb 26, 202510-KHealth Catalyst Files 2024 10-Kmedium
Jan 13, 20258-KHealth Catalyst to Present at J.P. Morgan Healthcare Conferencelow
Nov 14, 2024SC 13GSC 13G Filing
Nov 14, 2024SC 13G/ASC 13G/A Filing
Nov 12, 2024SC 13G/ASC 13G/A Filing
Nov 8, 2024SC 13G/ASC 13G/A Filing
Nov 7, 202410-QHealth Catalyst Files Q3 2024 10-Q Reportmedium
Nov 6, 20248-KHealth Catalyst to be Acquired for $17/Sharelow
Nov 4, 2024SC 13G/ASC 13G/A Filing

Risk Profile

Risk Assessment: Of HCAT's 25 recent filings, 1 were flagged as high-risk, 12 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Health Catalyst, Inc. Financial Summary (10-Q, Nov 10, 2025)
MetricValue
Revenue$236,457,000
Net Income-$86,949,000
Cash Position$40,305,000
Total Assets$587,128,000
Total Debt$153,139,000

Key Executives

  • Dan Burton

Industry Context

Health Catalyst operates in the healthcare technology sector, providing data and analytics solutions. The industry is characterized by a strong demand for improved efficiency and patient outcomes through data utilization. However, it faces competition from established players and emerging technology firms, with a constant need for innovation and integration with diverse healthcare systems.

Top Tags

Health Catalyst (4) · filing (3) · Healthcare Technology (3) · SEC Filing (3) · governance (3) · healthcare-technology (3) · 10-Q (3) · Financial Performance (2) · executive-compensation (2) · financials (2)

Key Numbers

Health Catalyst, Inc. Key Metrics
MetricValueContext
Net Loss$86.949MIncreased from $48.829M in 2024 for the nine months ended September 30
Total Revenue$236.457MIncreased from $226.978M in 2024 for the nine months ended September 30
Cash and Cash Equivalents$40.305MDecreased from $249.645M at December 31, 2024
Goodwill Impairment$28.769MRecorded for the nine months ended September 30, 2025
Debt Repayment$231.885MMade during the nine months ended September 30, 2025
Common Stock Outstanding70,730,884As of November 5, 2025
Total Revenue Growth4.18%Year-over-year for the nine months ended September 30
Technology Revenue Growth9.18%Year-over-year for the nine months ended September 30
Professional Services Revenue Change-4.39%Year-over-year for the nine months ended September 30
Cash and Cash Equivalents Change-83.8%From December 31, 2024, to September 30, 2025
Q2 2025 Total Revenue$76.5MIncreased 7.4% from Q2 2024's $71.2M
Q2 2025 Net Loss$25.3MWidened from Q2 2024's $22.1M
Q2 2025 Technology Revenue$50.1MIncreased 8.4% from Q2 2024's $46.2M
YTD 2025 Total Revenue$150.2MIncreased 6.9% from YTD 2024's $140.5M
YTD 2025 Net Loss$50.1MWidened from YTD 2024's $43.9M

Forward-Looking Statements

  • {"claim":"Other institutional investors may increase their positions in Health Catalyst, Inc. following Wellington Management Group LLP's disclosed stake.","entity":"Health Catalyst, Inc.","targetDate":"Next 6-12 months","confidence":"medium"}

Related Companies

MSFT · CERN · EPIC

Frequently Asked Questions

What are the latest SEC filings for Health Catalyst, Inc. (HCAT)?

Health Catalyst, Inc. has 34 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of HCAT filings?

Across 34 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 29 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Health Catalyst, Inc. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Health Catalyst, Inc. (HCAT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Health Catalyst, Inc.?

Key financial highlights from Health Catalyst, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for HCAT?

The investment thesis for HCAT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Health Catalyst, Inc.?

Key executives identified across Health Catalyst, Inc.'s filings include Dan Burton.

What are the main risk factors for Health Catalyst, Inc. stock?

Of HCAT's 25 assessed filings, 1 were flagged high-risk, 12 medium-risk, and 12 low-risk.

What are recent predictions and forward guidance from Health Catalyst, Inc.?

Recent forward-looking statements from Health Catalyst, Inc. include guidance on {"claim":"Other institutional investors may increase their positions in Health Catalyst, Inc. following Wellington Manag.

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.